Submit Manuscript  

Article Details


Toxicity and Tolerability of 177Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin – A Phase 2 Registry Study

Author(s):

Alireza Khatami *, Golmehr Sistani, Duncan E. K. Sutherland , Sarah DeBrabandere, Robert H. Reid and David T. Laidley   Pages 1 - 11 ( 11 )

Abstract:


Background: Peptide receptor radionuclide therapy (PRRT) has been recently approved for advanced, metastatic, or progressive neuroendocrine tumors (NETs).

Objective: This study reports the adverse events (AEs) observed with patient-tailored administered activity.

Methods: Fifty-two PRRT naive patients were treated with 177Lu-DOTATATE. The administered activity ranges between 2.78 and 5.55 GBq/cycle using the patient's unique characteristics (age, symptoms, blood work, and biomarkers).

Results: The protocol was well tolerated with the overwhelming majority of participants being forty- six (88%), completing all 4 induction therapy cycles. The median cumulative administered activity was 19.6 GBq (ranged 3.8-22.3 GBq). A total of 42/52 (81%) reported at least one symptom, and 43/52 (83%) had evidence of biochemical abnormality at enrollment that would meet grade 1 or 2 criteria for AEs. These symptoms only slightly increase with treatment to 50/52 (96%) and 51/52 (98%), respectively. The most common symptoms were mild fatigue (62%), shortness of breath (50%), nausea (44%), abdominal pain (38%), and musculoskeletal pain (37%). The most common biomarker abnormalities were mild anemia (81%), reduced estimated glomerular filtration rate (eGFR) (58%), increased alkaline phosphatase (ALP) (50%), and leukopenia (37%). Of critical importance, no 177Lu-DOTATATE related grade 3 or 4 AEs were observed.

Conclusion: Tailoring the administered activity of 177Lu-DOTATATE to the individual patient with a variety of NETs is both safe and well-tolerated. No patient developed severe grade 3 or 4 AEs. Most patients exhibit symptoms or biochemical abnormality before treatment and this only slightly worsens following induction therapy.

Keywords:

Toxicity, safety, neuroendocrine tumor, NET, PRRT, peptide receptor radionuclide therapy, DOTATAE, Lu-177.

Affiliation:

Division of Nuclear Medicine, Department of Medical Imaging, Western University, London, ON, Division of Nuclear Medicine, Department of Medical Imaging, Western University, London, ON, Division of Nuclear Medicine, Department of Medical Imaging, Western University, London, ON, Division of Nuclear Medicine, Department of Medical Imaging, Western University, London, ON, Division of Nuclear Medicine, Department of Medical Imaging, Western University, London, ON, Division of Nuclear Medicine, Department of Medical Imaging, Western University, London, ON



Read Full-Text article